Nice!_老虎社区_美港股上老虎

2021-12-15

Nice!

Pfizer Says Its Covid-19 Pill Likely Works Against Omicron<blockquote>辉瑞公司称其 Covid-19 药丸可能对奥密克戎有效</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":607810028,"tweetId":"607810028","gmtCreate":1639523894354,"gmtModify":1639523894622,"author":{"id":3575234837042918,"idStr":"3575234837042918","authorId":3575234837042918,"authorIdStr":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":26,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Nice!</body></html>","htmlText":"<html><head></head><body>Nice!</body></html>","text":"Nice!","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/607810028","repostId":1111446051,"repostType":4,"repost":{"id":"1111446051","kind":"news","pubTimestamp":1639523229,"share":"https://www.laohunote.com/m/news/1111446051?lang=zh_CN&edition=full","pubTime":"2021-12-15 07:07","market":"us","language":"en","title":"Pfizer Says Its Covid-19 Pill Likely Works Against Omicron<blockquote>辉瑞公司称其 Covid-19 药丸可能对奥密克戎有效</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111446051","media":"The Wall Street Journal","summary":"Preliminary laboratory tests gave encouraging signs that Pfizer Inc.’s PFE 0.62% experimental Covid-","content":" Preliminary laboratory tests gave encouraging signs that Pfizer Inc.’s PFE 0.62% experimental Covid-19 pill for the newly infected could work against Omicron, the company said.<blockquote>辉瑞公司表示，初步的实验室测试给出了令人鼓舞的迹象，表明辉瑞公司为新感染者研发的 PFE 0.62% 实验性 Covid-19 药丸可以对抗奥密克戎病。</blockquote> Pfizer also said Tuesday that a final analysis of late-stage study results confirmed the drug, named Paxlovid, was 89% effective at reducing the risk of hospitalization and death in adults at high risk of severe Covid-19.<blockquote>辉瑞公司周二还表示，对后期研究结果的最终分析证实，这种名为 Paxlovid 的药物在降低患有严重 Covid-19 高风险的成年人住院和死亡风险方面有 89% 的有效性。</blockquote> The positive results come as the Food and Drug Administration reviews whether to clear use of Paxlovid in high-risk adults, a decision that could come before the end of the year.<blockquote>积极的结果出现之际，美国食品和药物管理局正在审查是否允许在高危成年人中使用 Paxlovid，这一决定可能会在今年年底前做出。</blockquote> “This was a real home run, gives tremendous hope for another highly effective intervention,” Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.<blockquote>“辉瑞公司首席科学官米凯尔-多尔斯滕（Mikael Dolsten）在接受采访时说：”这是一个真正的本垒打，为另一次高效干预带来了巨大的希望。</blockquote> Meanwhile, a separate, preliminary analysis provided signs the drug may help people at low risk of severe Covid-19, such as vaccinated individuals who end up becoming sick.<blockquote>与此同时，一项单独的初步分析表明，该药物可能有助于重症 Covid-19 风险较低的人群，例如最终患病的接种疫苗的人。</blockquote> Paxlovid in the early study analysis reduced the risk of hospitalization and death by 70% in adults at low risk of severe Covid-19, though it failed to reduce or resolve their symptoms within four days.<blockquote>在早期研究分析中，Paxlovid将严重新冠肺炎低风险成年人的住院和死亡风险降低了70%，尽管它未能在四天内减轻或解决他们的症状。</blockquote> Study subjects who were at high risk of developing severe disease had to have at least one characteristic or underlying health condition such as being obese or elderly. The other study included people who were either unvaccinated and at low risk of developing severe disease, such as young and healthy individuals, or vaccinated people with at least one risk factor for developing severe disease.<blockquote>处于发生严重疾病高风险的研究受试者必须具有至少一种特征或潜在的健康状况，如肥胖或老年。另一项研究包括未接种疫苗且患严重疾病风险较低的人，如年轻健康的个体，或已接种疫苗且至少有一种患严重疾病风险因素的人。</blockquote> Both studies testing Paxlovid in people showed that the amount of virus, or viral load, in subjects who received the drug was significantly less than in the placebo groups, Pfizer said.<blockquote>辉瑞公司表示，这两项在人体中测试 Paxlovid 的研究都表明，接受该药物的受试者体内的病毒量或病毒载量明显少于安慰剂组。</blockquote> A lower viral load could mean less transmission of the virus.<blockquote>较低的病毒载量可能意味着病毒的传播较少。</blockquote> Citing the findings, some analysts said Paxlovid was likely to become the Covid-19 drug of choice for newly infected adults seeking to avoid severe disease. JP Morgan Chase &amp; Co. analysts estimated $18 billion in sales next year.<blockquote>一些分析师援引研究结果表示，Paxlovid 可能会成为寻求避免严重疾病的新感染成年人的首选 Covid-19 药物。摩根大通分析师估计明年的销售额为180亿美元。</blockquote> Pfizer shares rose 0.62% in Tuesday trading.<blockquote>辉瑞股价在周二交易中上涨 0.62%。</blockquote> Doctors and health experts have been looking for an antiviral like Paxlovid, which people could easily take at home within several days of symptoms emerging to prevent their cases from turning serious and requiring hospitalization.<blockquote>医生和健康专家一直在寻找像Paxlovid这样的抗病毒药物，人们可以在症状出现后的几天内轻松在家服用，以防止病情严重并需要住院治疗。</blockquote> The emergence of Omicron has shadowed the approach of such antivirals, however, because of uncertainty whether the new strain could elude treatments and vaccines.<blockquote>然而，奥密克戎病毒的出现给这种抗病毒药物的方法蒙上了阴影，因为不确定这种新毒株是否可以逃避治疗和疫苗。</blockquote> To make an assessment, drugmakers have been studying whether authorized and experimental Covid-19 drugs and vaccines are effective against Omicron.<blockquote>为了进行评估，制药商一直在研究授权和实验性的新冠肺炎药物和疫苗是否对奥密克戎有效。</blockquote> Doctors are increasingly turning to monoclonal-antibody drugs to treat high-risk patients who get sick with Covid-19. WSJ takes a look at how the therapies work and why they’re important for saving lives. Illustration: Jacob Reynolds/WSJ<blockquote>医生越来越多地转向单克隆抗体药物来治疗感染 Covid-19 的高危患者。《华尔街日报》探讨了这些疗法是如何发挥作用的，以及它们为何对拯救生命如此重要。插图：雅各布·雷诺兹/华尔街日报</blockquote> Researchers suspected Pfizer’s pill would hold up well because it stops the virus by blocking the activity of a key enzyme, known as protease, that the virus needs to replicate and isn’t believed to be mutated in Omicron.<blockquote>研究人员怀疑辉瑞公司的药丸会很有效，因为它通过阻断一种被称为蛋白酶的关键酶的活性来阻止病毒，而这种酶是病毒复制所需的，据信在奥密克戎不会发生变异。</blockquote> That is different from Covid-19 vaccines and some treatments that target a different part of the virus, the spike protein, that is the site of many Omicron mutations.<blockquote>这不同于新冠肺炎疫苗和一些针对病毒不同部分（刺突蛋白）的治疗方法，刺突蛋白是许多奥密克戎突变的位点。</blockquote> The early Pfizer laboratory tests showed that Paxlovid blocked the protease enzyme in Omicron, as well as other variants of concern, Dr. Dolsten said.<blockquote>Dolsten博士说，辉瑞实验室的早期测试表明，Paxlovid阻断了奥密克戎的蛋白酶，以及其他令人担忧的变异。</blockquote> “Without the protease functioning, the virus can’t replicate and cause disease,” Dr. Dolsten said. “I’m very convinced that the effects on Omicron by Paxlovid will be very substantial.”<blockquote>“多尔斯滕博士说：”没有蛋白酶的功能，病毒就无法复制并引起疾病。“我非常相信 Paxlovid 对奥密克戎的影响将非常大”。</blockquote> Pfizer said it plans on performing more testing to measure Paxlovid’s effectiveness against the variant.<blockquote>辉瑞公司表示，计划进行更多测试，以衡量 Paxlovid 对该变种的有效性。</blockquote> In November, Pfizer said an early look at a key study found Paxlovid was 89% effective at reducing the risk of hospitalization and death in high-risk adults.<blockquote>11 月，辉瑞公司表示，一项关键研究的早期研究发现，Paxlovid 在降低高危成年人住院和死亡风险方面有 89% 的有效性。</blockquote> The FDA has been waiting for the final results before making an authorization decision, Pfizer Chief Executive Albert Bourla said last week at The Wall Street Journal’s CEO Council.<blockquote>辉瑞公司首席执行官阿尔伯特-布尔拉（Albert Bourla）上周在《华尔街日报》首席执行官委员会上表示，美国食品和药物管理局一直在等待最终结果，然后再做出授权决定。</blockquote> In the final analysis, five of the 697 high-risk subjects who received the drug within three days of symptoms were hospitalized or died from Covid-19, compared with 44 out of 682 subjects who received a placebo, Pfizer said.<blockquote>辉瑞公司表示，在最终分析中，在出现症状三天内接受该药物的 697 名高危受试者中有 5 人死于 Covid-19，而接受安慰剂的 682 名受试者中有 44 人死于 Covid-19。</blockquote> Nine study volunteers who received a placebo died, compared with none in the treatment arm, the company said.<blockquote>该公司表示，接受安慰剂的九名研究志愿者死亡，而治疗组中没有一人死亡。</blockquote> Researchers also reported the drug was 88% effective if taken within five days of symptoms.<blockquote>研究人员还报告说，如果在症状出现五天内服用，该药物的有效率为 88%。</blockquote> The final study analysis of another oral antiviral, from Merck &amp; Co. and partner Ridgeback Biotherapeutics LP, showed a 30% risk reduction, lower than the 50% found during an early look.<blockquote>默克公司和合作伙伴 Ridgeback Biotherapeutics LP 对另一种口服抗病毒药物进行的最终研究分析显示，风险降低了 30%，低于早期研究中发现的 50%。</blockquote> Separately, Pfizer has been testing Paxlovid’s effectiveness in people at low risk of developing severe disease, including some who were vaccinated.<blockquote>另外，辉瑞公司一直在测试 Paxlovid 在患严重疾病风险较低的人群中的有效性，其中包括一些接种过疫苗的人。</blockquote> The company’s preliminary look at the results found Paxlovid failed to resolve or consistently reduce self-reported symptoms within four days, which was the study’s main goal and a way of determining whether an antiviral is effective.<blockquote>该公司对结果的初步研究发现，Paxlovid 未能在四天内解决或持续减轻自我报告的症状，而这正是这项研究的主要目标，也是确定抗病毒药物是否有效的一种方法。</blockquote> Two of the 333 low-risk subjects who got Paxlovid were hospitalized, however, compared with eight of 329 subjects who received a placebo, resulting in the 70% efficacy, Pfizer said.<blockquote>然而，辉瑞公司表示，接受 Paxlovid 治疗的 333 名低风险受试者中有 2 名住院治疗，而接受安慰剂治疗的 329 名受试者中有 8 名住院治疗，疗效为 70%。</blockquote> No subjects had died from Covid-19 in the analysis, which looked at how about 45% of the total number of subjects targeted for the study fared.<blockquote>在这项分析中，没有受试者死于新冠肺炎，该分析着眼于该研究目标受试者总数中约45%的情况。</blockquote> Dr. Dolsten said Pfizer planned to discuss with health authorities in the U.S. and other countries about potentially making the drug available to low-risk people, and whether Pfizer should do more testing.<blockquote>多尔斯滕博士表示，辉瑞计划与美国和其他国家的卫生当局讨论向低风险人群提供该药物的可能性，以及辉瑞是否应该进行更多测试。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Says Its Covid-19 Pill Likely Works Against Omicron<blockquote>辉瑞公司称其 Covid-19 药丸可能对奥密克戎有效</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Says Its Covid-19 Pill Likely Works Against Omicron<blockquote>辉瑞公司称其 Covid-19 药丸可能对奥密克戎有效</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nThe Wall Street Journal2021-12-15 07:07\n\n</h4>\n</header>\n<article>\n Preliminary laboratory tests gave encouraging signs that Pfizer Inc.’s PFE 0.62% experimental Covid-19 pill for the newly infected could work against Omicron, the company said.<blockquote>辉瑞公司表示，初步的实验室测试给出了令人鼓舞的迹象，表明辉瑞公司为新感染者研发的 PFE 0.62% 实验性 Covid-19 药丸可以对抗奥密克戎病。</blockquote> Pfizer also said Tuesday that a final analysis of late-stage study results confirmed the drug, named Paxlovid, was 89% effective at reducing the risk of hospitalization and death in adults at high risk of severe Covid-19.<blockquote>辉瑞公司周二还表示，对后期研究结果的最终分析证实，这种名为 Paxlovid 的药物在降低患有严重 Covid-19 高风险的成年人住院和死亡风险方面有 89% 的有效性。</blockquote> The positive results come as the Food and Drug Administration reviews whether to clear use of Paxlovid in high-risk adults, a decision that could come before the end of the year.<blockquote>积极的结果出现之际，美国食品和药物管理局正在审查是否允许在高危成年人中使用 Paxlovid，这一决定可能会在今年年底前做出。</blockquote> “This was a real home run, gives tremendous hope for another highly effective intervention,” Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.<blockquote>“辉瑞公司首席科学官米凯尔-多尔斯滕（Mikael Dolsten）在接受采访时说：”这是一个真正的本垒打，为另一次高效干预带来了巨大的希望。</blockquote> Meanwhile, a separate, preliminary analysis provided signs the drug may help people at low risk of severe Covid-19, such as vaccinated individuals who end up becoming sick.<blockquote>与此同时，一项单独的初步分析表明，该药物可能有助于重症 Covid-19 风险较低的人群，例如最终患病的接种疫苗的人。</blockquote> Paxlovid in the early study analysis reduced the risk of hospitalization and death by 70% in adults at low risk of severe Covid-19, though it failed to reduce or resolve their symptoms within four days.<blockquote>在早期研究分析中，Paxlovid将严重新冠肺炎低风险成年人的住院和死亡风险降低了70%，尽管它未能在四天内减轻或解决他们的症状。</blockquote> Study subjects who were at high risk of developing severe disease had to have at least one characteristic or underlying health condition such as being obese or elderly. The other study included people who were either unvaccinated and at low risk of developing severe disease, such as young and healthy individuals, or vaccinated people with at least one risk factor for developing severe disease.<blockquote>处于发生严重疾病高风险的研究受试者必须具有至少一种特征或潜在的健康状况，如肥胖或老年。另一项研究包括未接种疫苗且患严重疾病风险较低的人，如年轻健康的个体，或已接种疫苗且至少有一种患严重疾病风险因素的人。</blockquote> Both studies testing Paxlovid in people showed that the amount of virus, or viral load, in subjects who received the drug was significantly less than in the placebo groups, Pfizer said.<blockquote>辉瑞公司表示，这两项在人体中测试 Paxlovid 的研究都表明，接受该药物的受试者体内的病毒量或病毒载量明显少于安慰剂组。</blockquote> A lower viral load could mean less transmission of the virus.<blockquote>较低的病毒载量可能意味着病毒的传播较少。</blockquote> Citing the findings, some analysts said Paxlovid was likely to become the Covid-19 drug of choice for newly infected adults seeking to avoid severe disease. JP Morgan Chase &amp; Co. analysts estimated $18 billion in sales next year.<blockquote>一些分析师援引研究结果表示，Paxlovid 可能会成为寻求避免严重疾病的新感染成年人的首选 Covid-19 药物。摩根大通分析师估计明年的销售额为180亿美元。</blockquote> Pfizer shares rose 0.62% in Tuesday trading.<blockquote>辉瑞股价在周二交易中上涨 0.62%。</blockquote> Doctors and health experts have been looking for an antiviral like Paxlovid, which people could easily take at home within several days of symptoms emerging to prevent their cases from turning serious and requiring hospitalization.<blockquote>医生和健康专家一直在寻找像Paxlovid这样的抗病毒药物，人们可以在症状出现后的几天内轻松在家服用，以防止病情严重并需要住院治疗。</blockquote> The emergence of Omicron has shadowed the approach of such antivirals, however, because of uncertainty whether the new strain could elude treatments and vaccines.<blockquote>然而，奥密克戎病毒的出现给这种抗病毒药物的方法蒙上了阴影，因为不确定这种新毒株是否可以逃避治疗和疫苗。</blockquote> To make an assessment, drugmakers have been studying whether authorized and experimental Covid-19 drugs and vaccines are effective against Omicron.<blockquote>为了进行评估，制药商一直在研究授权和实验性的新冠肺炎药物和疫苗是否对奥密克戎有效。</blockquote> Doctors are increasingly turning to monoclonal-antibody drugs to treat high-risk patients who get sick with Covid-19. WSJ takes a look at how the therapies work and why they’re important for saving lives. Illustration: Jacob Reynolds/WSJ<blockquote>医生越来越多地转向单克隆抗体药物来治疗感染 Covid-19 的高危患者。《华尔街日报》探讨了这些疗法是如何发挥作用的，以及它们为何对拯救生命如此重要。插图：雅各布·雷诺兹/华尔街日报</blockquote> Researchers suspected Pfizer’s pill would hold up well because it stops the virus by blocking the activity of a key enzyme, known as protease, that the virus needs to replicate and isn’t believed to be mutated in Omicron.<blockquote>研究人员怀疑辉瑞公司的药丸会很有效，因为它通过阻断一种被称为蛋白酶的关键酶的活性来阻止病毒，而这种酶是病毒复制所需的，据信在奥密克戎不会发生变异。</blockquote> That is different from Covid-19 vaccines and some treatments that target a different part of the virus, the spike protein, that is the site of many Omicron mutations.<blockquote>这不同于新冠肺炎疫苗和一些针对病毒不同部分（刺突蛋白）的治疗方法，刺突蛋白是许多奥密克戎突变的位点。</blockquote> The early Pfizer laboratory tests showed that Paxlovid blocked the protease enzyme in Omicron, as well as other variants of concern, Dr. Dolsten said.<blockquote>Dolsten博士说，辉瑞实验室的早期测试表明，Paxlovid阻断了奥密克戎的蛋白酶，以及其他令人担忧的变异。</blockquote> “Without the protease functioning, the virus can’t replicate and cause disease,” Dr. Dolsten said. “I’m very convinced that the effects on Omicron by Paxlovid will be very substantial.”<blockquote>“多尔斯滕博士说：”没有蛋白酶的功能，病毒就无法复制并引起疾病。“我非常相信 Paxlovid 对奥密克戎的影响将非常大”。</blockquote> Pfizer said it plans on performing more testing to measure Paxlovid’s effectiveness against the variant.<blockquote>辉瑞公司表示，计划进行更多测试，以衡量 Paxlovid 对该变种的有效性。</blockquote> In November, Pfizer said an early look at a key study found Paxlovid was 89% effective at reducing the risk of hospitalization and death in high-risk adults.<blockquote>11 月，辉瑞公司表示，一项关键研究的早期研究发现，Paxlovid 在降低高危成年人住院和死亡风险方面有 89% 的有效性。</blockquote> The FDA has been waiting for the final results before making an authorization decision, Pfizer Chief Executive Albert Bourla said last week at The Wall Street Journal’s CEO Council.<blockquote>辉瑞公司首席执行官阿尔伯特-布尔拉（Albert Bourla）上周在《华尔街日报》首席执行官委员会上表示，美国食品和药物管理局一直在等待最终结果，然后再做出授权决定。</blockquote> In the final analysis, five of the 697 high-risk subjects who received the drug within three days of symptoms were hospitalized or died from Covid-19, compared with 44 out of 682 subjects who received a placebo, Pfizer said.<blockquote>辉瑞公司表示，在最终分析中，在出现症状三天内接受该药物的 697 名高危受试者中有 5 人死于 Covid-19，而接受安慰剂的 682 名受试者中有 44 人死于 Covid-19。</blockquote> Nine study volunteers who received a placebo died, compared with none in the treatment arm, the company said.<blockquote>该公司表示，接受安慰剂的九名研究志愿者死亡，而治疗组中没有一人死亡。</blockquote> Researchers also reported the drug was 88% effective if taken within five days of symptoms.<blockquote>研究人员还报告说，如果在症状出现五天内服用，该药物的有效率为 88%。</blockquote> The final study analysis of another oral antiviral, from Merck &amp; Co. and partner Ridgeback Biotherapeutics LP, showed a 30% risk reduction, lower than the 50% found during an early look.<blockquote>默克公司和合作伙伴 Ridgeback Biotherapeutics LP 对另一种口服抗病毒药物进行的最终研究分析显示，风险降低了 30%，低于早期研究中发现的 50%。</blockquote> Separately, Pfizer has been testing Paxlovid’s effectiveness in people at low risk of developing severe disease, including some who were vaccinated.<blockquote>另外，辉瑞公司一直在测试 Paxlovid 在患严重疾病风险较低的人群中的有效性，其中包括一些接种过疫苗的人。</blockquote> The company’s preliminary look at the results found Paxlovid failed to resolve or consistently reduce self-reported symptoms within four days, which was the study’s main goal and a way of determining whether an antiviral is effective.<blockquote>该公司对结果的初步研究发现，Paxlovid 未能在四天内解决或持续减轻自我报告的症状，而这正是这项研究的主要目标，也是确定抗病毒药物是否有效的一种方法。</blockquote> Two of the 333 low-risk subjects who got Paxlovid were hospitalized, however, compared with eight of 329 subjects who received a placebo, resulting in the 70% efficacy, Pfizer said.<blockquote>然而，辉瑞公司表示，接受 Paxlovid 治疗的 333 名低风险受试者中有 2 名住院治疗，而接受安慰剂治疗的 329 名受试者中有 8 名住院治疗，疗效为 70%。</blockquote> No subjects had died from Covid-19 in the analysis, which looked at how about 45% of the total number of subjects targeted for the study fared.<blockquote>在这项分析中，没有受试者死于新冠肺炎，该分析着眼于该研究目标受试者总数中约45%的情况。</blockquote> Dr. Dolsten said Pfizer planned to discuss with health authorities in the U.S. and other countries about potentially making the drug available to low-risk people, and whether Pfizer should do more testing.<blockquote>多尔斯滕博士表示，辉瑞计划与美国和其他国家的卫生当局讨论向低风险人群提供该药物的可能性，以及辉瑞是否应该进行更多测试。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.wsj.com/articles/pfizer-says-its-covid-19-pill-likely-works-against-omicron-11639482302?mod=hp_lead_pos1\">The Wall Street Journal</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.wsj.com/articles/pfizer-says-its-covid-19-pill-likely-works-against-omicron-11639482302?mod=hp_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111446051","content_text":"Preliminary laboratory tests gave encouraging signs that Pfizer Inc.’s PFE 0.62% experimental Covid-19 pill for the newly infected could work against Omicron, the company said.\n\nPfizer also said Tuesday that a final analysis of late-stage study results confirmed the drug, named Paxlovid, was 89% effective at reducing the risk of hospitalization and death in adults at high risk of severe Covid-19.\n\nThe positive results come as the Food and Drug Administration reviews whether to clear use of Paxlovid in high-risk adults, a decision that could come before the end of the year.\n\n“This was a real home run, gives tremendous hope for another highly effective intervention,” Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.\n\nMeanwhile, a separate, preliminary analysis provided signs the drug may help people at low risk of severe Covid-19, such as vaccinated individuals who end up becoming sick.\n\nPaxlovid in the early study analysis reduced the risk of hospitalization and death by 70% in adults at low risk of severe Covid-19, though it failed to reduce or resolve their symptoms within four days.\n\nStudy subjects who were at high risk of developing severe disease had to have at least one characteristic or underlying health condition such as being obese or elderly. The other study included people who were either unvaccinated and at low risk of developing severe disease, such as young and healthy individuals, or vaccinated people with at least one risk factor for developing severe disease.\n\nBoth studies testing Paxlovid in people showed that the amount of virus, or viral load, in subjects who received the drug was significantly less than in the placebo groups, Pfizer said.\n\nA lower viral load could mean less transmission of the virus.\n\nCiting the findings, some analysts said Paxlovid was likely to become the Covid-19 drug of choice for newly infected adults seeking to avoid severe disease. JP Morgan Chase & Co. analysts estimated $18 billion in sales next year.\n\nPfizer shares rose 0.62% in Tuesday trading.\n\nDoctors and health experts have been looking for an antiviral like Paxlovid, which people could easily take at home within several days of symptoms emerging to prevent their cases from turning serious and requiring hospitalization.\n\nThe emergence of Omicron has shadowed the approach of such antivirals, however, because of uncertainty whether the new strain could elude treatments and vaccines.\n\nTo make an assessment, drugmakers have been studying whether authorized and experimental Covid-19 drugs and vaccines are effective against Omicron.\n\nDoctors are increasingly turning to monoclonal-antibody drugs to treat high-risk patients who get sick with Covid-19. WSJ takes a look at how the therapies work and why they’re important for saving lives. Illustration: Jacob Reynolds/WSJ\nResearchers suspected Pfizer’s pill would hold up well because it stops the virus by blocking the activity of a key enzyme, known as protease, that the virus needs to replicate and isn’t believed to be mutated in Omicron.\n\n\nThat is different from Covid-19 vaccines and some treatments that target a different part of the virus, the spike protein, that is the site of many Omicron mutations.\n\nThe early Pfizer laboratory tests showed that Paxlovid blocked the protease enzyme in Omicron, as well as other variants of concern, Dr. Dolsten said.\n\n“Without the protease functioning, the virus can’t replicate and cause disease,” Dr. Dolsten said. “I’m very convinced that the effects on Omicron by Paxlovid will be very substantial.”\n\nPfizer said it plans on performing more testing to measure Paxlovid’s effectiveness against the variant.\n\nIn November, Pfizer said an early look at a key study found Paxlovid was 89% effective at reducing the risk of hospitalization and death in high-risk adults.\n\nThe FDA has been waiting for the final results before making an authorization decision, Pfizer Chief Executive Albert Bourla said last week at The Wall Street Journal’s CEO Council.\n\nIn the final analysis, five of the 697 high-risk subjects who received the drug within three days of symptoms were hospitalized or died from Covid-19, compared with 44 out of 682 subjects who received a placebo, Pfizer said.\n\nNine study volunteers who received a placebo died, compared with none in the treatment arm, the company said.\n\nResearchers also reported the drug was 88% effective if taken within five days of symptoms.\n\nThe final study analysis of another oral antiviral, from Merck & Co. and partner Ridgeback Biotherapeutics LP, showed a 30% risk reduction, lower than the 50% found during an early look.\n\nSeparately, Pfizer has been testing Paxlovid’s effectiveness in people at low risk of developing severe disease, including some who were vaccinated.\n\nThe company’s preliminary look at the results found Paxlovid failed to resolve or consistently reduce self-reported symptoms within four days, which was the study’s main goal and a way of determining whether an antiviral is effective.\n\nTwo of the 333 low-risk subjects who got Paxlovid were hospitalized, however, compared with eight of 329 subjects who received a placebo, resulting in the 70% efficacy, Pfizer said.\n\n\nNo subjects had died from Covid-19 in the analysis, which looked at how about 45% of the total number of subjects targeted for the study fared.\n\nDr. Dolsten said Pfizer planned to discuss with health authorities in the U.S. and other countries about potentially making the drug available to low-risk people, and whether Pfizer should do more testing.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1236,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/607810028"}